|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM361414471 |
| 003 |
DE-627 |
| 005 |
20231226085104.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202306158
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1204.xml
|
| 035 |
|
|
|a (DE-627)NLM361414471
|
| 035 |
|
|
|a (NLM)37643537
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liang, Jie
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Outer Membrane Vesicle-Based Nanohybrids Target Tumor-Associated Macrophages to Enhance Trained Immunity-Related Vaccine-Generated Antitumor Activity
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.11.2023
|
| 500 |
|
|
|a Date Revised 17.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Trained immunity refers to the innate immune system building memory-like features in response to subsequent infections and vaccinations. Compared with classical tumor vaccines, trained immunity-related vaccines (TIrV) are independent of tumor-specific antigens. Bacterial outer membrane vesicles (OMVs) contain an abundance of PAMPs and have the potential to act as TIrV-inducer, but face challenges in endotoxin tolerance, systemic delivery, long-term training, and trained tumor-associated macrophage (TAM)-mediated antitumor phagocytosis. Here, an OMV-based TIrV is developed, OMV nanohybrids (OMV-SIRPαCaP/GM-CSF) for exerting vaccine-enhanced antitumor activity. In the bone marrow, GM-CSF-assisted OMVs train bone marrow progenitor cells and monocytes, which are inherited by TAMs. In tumor tissues, SIRPα-Fc-assisted OMVs trigger TAM-mediated phagocytosis. This TIrV can be identified by metabolic and epigenetic rewiring using transposase-accessible chromatin (ATAC) and transcriptome sequencing. Furthermore, it is found that the TIrV-mediated antitumor mechanism in the MC38 tumor model (TAM-hot and T cell-cold) is trained immunity and activated T cell response, whereas in the B16-F10 tumor model (T cell-hot and TAM-cold) is primarily mediated by trained immunity. This study not only develops and identifies OMV-based TIrV, but also investigates the trained immunity signatures and therapeutic mechanisms, providing a basis for further vaccination strategies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a antitumor mechanisms
|
| 650 |
|
4 |
|a outer membrane vesicle-based nanohybrids
|
| 650 |
|
4 |
|a trained immunity signatures
|
| 650 |
|
4 |
|a trained immunity-related vaccines (TIrV)
|
| 650 |
|
4 |
|a tumor-associated macrophages (TAMs)
|
| 650 |
|
7 |
|a Granulocyte-Macrophage Colony-Stimulating Factor
|2 NLM
|
| 650 |
|
7 |
|a 83869-56-1
|2 NLM
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Fei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Keman
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, Nana
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, Xiaotu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Qingqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Xiaoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xinwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Jian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Xiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nie, Guangjun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 46 vom: 20. Nov., Seite e2306158
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:46
|g day:20
|g month:11
|g pages:e2306158
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202306158
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 46
|b 20
|c 11
|h e2306158
|